Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
Lancet 2023 Apr 8;401(10383):1159-1171 DOI 10.1016/S0140-6736(23)00061-2
Etrasimod demonstrated significant efficacy in achieving clinical remission, and was well tolerated compared to placebo in an induction and maintenance therapy.
Sandborn er al. presents the results of two phase 3 trials, ELEVATE UC 52, and ELEVATE UC 12, evaluating the safety and efficacy of etrasimod in adult patients with moderately to severely active ulcerative colitis.
